Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
Reduces process development time by an estimated 40 percent Enables biopharmaceutical companies to increase the speed to clinical manufacturing Adds to company’s best-in-class VirusExpress® Lentiviral Production Platform Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral…
